Fort Worth-based NanOlogy, LLC, a clinical-stage oncology company, has named veteran biopharma executive David Arthur as its new chief executive officer.

Arthur becomes the company’s chief executive as NanOlogy moves toward later-stage development and commercialization. Founder H. Paul Dorman remains chairman.

The appointment comes as NanOlogy works to advance its Large Surface Area Microparticles (LSAM) drug portfolio, including a program targeting Diffuse Intrinsic Pontine Glioma (DIPG), a rare and aggressive pediatric brain cancer with limited treatment options.

NanOlogy has advanced LSAM-based investigational drugs through clinical trials in multiple solid tumor indications, including pancreatic, lung, bladder, peritoneal, ovarian, prostate, and dermal cancers, according to the company.

Dorman said Arthur’s experience will help accelerate the company’s development efforts and strengthen its ability to identify partners to move those programs forward.

“We believe David is a great addition to the team and will accelerate our existing drug development activities, business development plans, and new drug development programs,” Dorman said in a statement.

Dorman said the company is completing Investigational New Drug–enabling studies for a rare pediatric brainstem tumor and plans to submit an IND application to the U.S. Food and Drug Administration in mid-2026.

Earlier clinical work by NanOlogy showed that its tumor-directed LSAM approach could deliver chemotherapy locally with limited systemic toxicity, as Dallas Innovates has previously reported.

A scaling CEO for a pivotal phase

Arthur brings more than 35 years of experience across pharmaceutical product development, operations, strategy, and commercialization.

Most recently, he served as CEO of Houston-based Salarius Pharmaceuticals, where he built the company into a multiproduct, clinical-stage oncology business and led its public listing on the Nasdaq exchange. Earlier in his career, Arthur spent more than two decades in executive roles at Eli Lilly and Boehringer Ingelheim.

Arthur said he was drawn to NanOlogy’s focus on localized cancer therapies and the potential to improve patient outcomes while reducing systemic side effects.

“I am extremely impressed by the progress NanOlogy has made in drug development and the potential for these intratumoral drugs,” Arthur said. He also pointed to other local routes of administration, including inhalation, as alternatives to traditional systemic cancer treatments.

“My goal will be to rapidly build upon this progress and execute a strategy that benefits cancer patients and creates value for shareholders,” he said.

The technology behind the approach

NanOlogy is a private clinical-stage oncology company developing treatments for solid tumors using drugs optimized for intratumoral delivery—an approach designed to improve tumor response while minimizing systemic toxicity.

The company’s platform is powered by CritiTech Particle Engineering Solutions’ trademarked Purcision technology, which produces Large Surface Area Microparticles of pure drug for direct local delivery, NanOlogy said.

Dallas Innovates has previously reported that the Purcision platform can reduce chemotherapy drug crystals by up to 400 times, enabling so-called “naked” drug particles to remain at the injection site and form a localized drug depot without the use of surfactants or coatings.

NanOlogy’s LSAM-based programs have also been explored in combination with systemic immune checkpoint inhibitors, following the issuance of a U.S. patent covering the use of LSAM taxanes alongside immunotherapies to enhance the body’s immune response against solid tumors.

Quincy Preston contributed to this report.

Don’t miss what’s next. Subscribe to Dallas Innovates.

Track Dallas-Fort Worth’s business and innovation landscape with our curated news in your inbox Tuesday-Thursday.